Hip Structure Analysis by DXA of Teriparatide Treatment: A 24-month Follow-up Clinical Study

Overview

Journal J Orthop

Specialty Orthopedics

Date 2016 Sep 23

PMID 27656075

Citations 3

Authors

Takeshi Mochizuki

Koichiro Yano

Katsunori Ikari

Kosei Kawakami

Ryo Hiroshima

Naoko Koenuma

Mina Ishibashi

Toshikatsu Shirahata

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to perform a hip structure analysis (HSA) of teriparatide (TPTD) treatment in women with postmenopausal osteoporosis.

Methods: The study included 96 patients with postmenopausal osteoporosis and received 20 μg TPTD daily. HSA was performed by dual-energy X-ray absorptiometry.

Results: The percent changes from baseline for the cross-sectional moment of inertia, section modulus, buckling ratio, and femoral strength index based on HSA results were 9.8% (p < 0.01), 10.7%, 3.3%, and 14.9% (p < 0.01), respectively, at 24 months.

Conclusion: Based on the HSA results obtained with DXA, TPTD was effective for hip structures.

Citing Articles

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.

Sone T, Ohnaru K, Sugai T, Yamashita A, Okimoto N, Inoue T Arch Osteoporos. 2023; 18(1):146.

PMID: 38030806 PMC: 10687120. DOI: 10.1007/s11657-023-01344-5.

Comparison of different parameters between daily and twice-weekly teriparatide in postmenopausal women with severe osteoporosis.

Mochizuki T, Yano K, Ikari K, Okazaki K J Bone Miner Metab. 2023; 41(2):220-226.

PMID: 36625920 DOI: 10.1007/s00774-022-01398-4.

Comparison of femur stiffness measured from DXA and QCT for assessment of hip fracture risk.

Luo Y, Yang H J Bone Miner Metab. 2018; 37(2):342-350.

PMID: 29671044 DOI: 10.1007/s00774-018-0926-z.

References

Hansen S, Hauge E, Jensen J, Brixen K . Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res. 2012; 28(4):736-45. DOI: 10.1002/jbmr.1784. View

Uusi-Rasi K, Semanick L, Zanchetta J, Bogado C, Eriksen E, Sato M . Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005; 36(6):948-58. DOI: 10.1016/j.bone.2005.03.003. View

Dobnig H, Turner R . The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138(11):4607-12. DOI: 10.1210/endo.138.11.5505. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T . A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab. 2004; 22(5):469-78. DOI: 10.1007/s00774-004-0509-z. View

Yoshikawa T, Turner C, Peacock M, Slemenda C, Weaver C, Teegarden D . Geometric structure of the femoral neck measured using dual-energy x-ray absorptiometry. J Bone Miner Res. 1994; 9(7):1053-64. DOI: 10.1002/jbmr.5650090713. View

Kanis J, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B . Assessment of fracture risk. Osteoporos Int. 2004; 16(6):581-9. DOI: 10.1007/s00198-004-1780-5. View

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T . The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res. 2002; 4(5):281-9. PMC: 128939. DOI: 10.1186/ar431. View

10.

Reeve J, Meunier P, Parsons J, Bernat M, BIJVOET O, Courpron P . Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980; 280(6228):1340-4. PMC: 1601798. DOI: 10.1136/bmj.280.6228.1340. View

11.

Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner M, Nakamura T . Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label.... Bone. 2010; 47(3):493-502. DOI: 10.1016/j.bone.2010.05.022. View

12.

McClung M, San Martin J, Miller P, Civitelli R, Bandeira F, Omizo M . Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165(15):1762-8. DOI: 10.1001/archinte.165.15.1762. View

13.

Shane E, Burr D, Ebeling P, Abrahamsen B, Adler R, Brown T . Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25(11):2267-94. DOI: 10.1002/jbmr.253. View

14.

Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T . A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009; 44(6):1078-84. DOI: 10.1016/j.bone.2009.02.016. View

15.

Ma Y, Zeng Q, Chiang A, Burr D, Li J, Dobnig H . Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone. 2013; 59:139-47. DOI: 10.1016/j.bone.2013.11.011. View

16.

Momohara S, Okamoto H, Yago T, Furuya T, Nanke Y, Kotake S . The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod Rheumatol. 2006; 15(6):410-4. DOI: 10.1007/s10165-005-0435-5. View

17.

Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R . Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-99. DOI: 10.1056/NEJMoa030897. View

18.

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M, Martin T . Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20(3):345-57. DOI: 10.1210/edrv.20.3.0367. View

19.

Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K . Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab. 2004; 22(5):462-8. DOI: 10.1007/s00774-004-0508-0. View

20.

Yoshimura N, Suzuki T, Hosoi T, Orimo H . Epidemiology of hip fracture in Japan: incidence and risk factors. J Bone Miner Metab. 2005; 23 Suppl:78-80. DOI: 10.1007/BF03026328. View